ObsEva SA is a clinical stage, Swiss biopharmaceutical company dedicated to the development and commercialization of innovative drugs for women’s reproductive medicine.
Our management & collaborators combine successful experiences and track records in managing drug development and business development in large pharma & biotech companies.
The Board of Directors is composed of founders, international investors specialised in biotech and independent executives from top pharma companies.
ObsEva also benefits from the expertise of an independent & international advisory team (Scientific Advisory Board) composed of high level, academic specialists in OB-GYN and reproductive medicine.
ObsEva has worldwide exclusive licenses for an orally active, Oxytocin receptor Antagonist (OBE001) and an orally active, Prostaglandin F2α receptor Antagonist (OBE002).
Partnering is important to fast developing specialty biopharmaceutical companies. ObsEva is building its clinical product portfolio around multiple collaborations demonstrating the company’s ability to manage close collaborations with integrity, transparency and commitment.
How to contact ObsEva ?» contact us